Results 151 to 160 of about 13,244 (270)

Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma. [PDF]

open access: yesAm J Hematol
Smith SD   +12 more
europepmc   +1 more source

Best practices for respectful collaborative research on caribou (Rangifer tarandus) between Indigenous knowledge systems and Western science approaches: A systematic map of past mapping and modelling studies presents bright spots and room for improvement

open access: yesEcological Solutions and Evidence, Volume 7, Issue 4, October–December 2026.
Despite growing efforts to bring Indigenous and Western knowledge together in caribou research, inconsistent reporting of collaboration, ethics, knowledge sharing and Indigenous governance over data continue to limit transparency, accountability and true co‐production of knowledge.
Kimberly Klenk   +14 more
wiley   +1 more source

Tuktuit: Caribou

open access: yesJournal of Religion & Film
This is a review of the short film, Tuktuit: Caribou (2026), directed by Lindsay Aksarniq McIntyre.
openaire   +1 more source

Humans are not unique: difficult birth is common in placental mammals

open access: yesBiological Reviews, Volume 101, Issue 5, Page 2214-2239, October 2026.
ABSTRACT Human childbirth is widely presumed to be uniquely difficult and dangerous compared to birth in other mammals. Tight fetopelvic proportions can result in obstructed labour and contribute to high rates of maternal and neonatal mortality. Ideas summarised under the ‘obstetrical dilemma’ have contributed to this assumption by explaining difficult
Nicole D. S. Grunstra
wiley   +1 more source

Survival Outcomes in Chronic Lymphocytic Leukemia During the Novel Agent Era: A Population‐Based Analysis

open access: yesCancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Chemoimmunotherapy (CIT) had long been used to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) until 2014 when the first novel agent, ibrutinib, was approved in the United States. Numerous novel therapies have since become available.
Mengyang Di   +8 more
wiley   +1 more source

Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis

open access: yesCancer, Volume 132, Issue 19, 1 October 2026.
Abstract Background Ciltacabtagene autoleucel (cilta‐cel), an anti–B‐cell maturation antigen (BCMA) chimeric antigen receptor T‐cell (CAR‐T) therapy, is approved for relapsed/refractory multiple myeloma (RRMM). Methods Using the Center for International Blood and Marrow Transplant Research registry, this study evaluated outcomes of frail patients ...
Hira Mian   +31 more
wiley   +1 more source

Home - About - Disclaimer - Privacy